NASDAQ:FLGT Fulgent Genetics (FLGT) Stock Price, News & Analysis $23.66 +0.67 (+2.91%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$22.98▼$23.6650-Day Range$19.09▼$23.6652-Week Range$18.91▼$44.09Volume144,961 shsAverage Volume190,321 shsMarket Capitalization$707.91 millionP/E RatioN/ADividend YieldN/APrice Target$30.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Fulgent Genetics alerts: Email Address Fulgent Genetics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside26.8% Upside$30.00 Price TargetShort InterestBearish4.06% of Float Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment0.97Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.12) to ($2.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.22 out of 5 starsMedical Sector174th out of 936 stocksMedical Laboratories Industry7th out of 18 stocks 3.0 Analyst's Opinion Consensus RatingFulgent Genetics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageFulgent Genetics has received no research coverage in the past 90 days.Read more about Fulgent Genetics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.06% of the float of Fulgent Genetics has been sold short.Short Interest Ratio / Days to CoverFulgent Genetics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Fulgent Genetics has recently increased by 0.24%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldFulgent Genetics does not currently pay a dividend.Dividend GrowthFulgent Genetics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreFulgent Genetics has received a 58.06% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Private genetic testing services", "Private infectious disease diagnostics services", and "Private medical laboratory services" products. See details.Environmental SustainabilityThe Environmental Impact score for Fulgent Genetics is -0.67. Previous Next 3.3 News and Social Media Coverage News SentimentFulgent Genetics has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Fulgent Genetics this week, compared to 1 article on an average week.Search InterestOnly 19 people have searched for FLGT on MarketBeat in the last 30 days. This is a decrease of -24% compared to the previous 30 days.MarketBeat Follows4 people have added Fulgent Genetics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fulgent Genetics insiders have not sold or bought any company stock.Percentage Held by Insiders31.76% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.06% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fulgent Genetics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Fulgent Genetics are expected to grow in the coming year, from ($2.12) to ($2.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fulgent Genetics is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fulgent Genetics is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFulgent Genetics has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Fulgent Genetics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Fulgent Genetics Stock (NASDAQ:FLGT)Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.Read More FLGT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FLGT Stock News HeadlinesJuly 21, 2024 | americanbankingnews.comFulgent Genetics (NASDAQ:FLGT) Shares Gap Up to $22.02June 10, 2024 | globenewswire.comPress release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global MarketingJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 6, 2024 | seekingalpha.comFulgent Genetics: Growth Is ReturningJune 3, 2024 | businesswire.comFulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck CancerMay 24, 2024 | businesswire.comFulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual MeetingMay 14, 2024 | businesswire.comMoffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer TherapeuticsMay 6, 2024 | finance.yahoo.comFulgent Genetics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 4, 2024 | finance.yahoo.comFulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2024 Earnings Call TranscriptMay 4, 2024 | finance.yahoo.comFulgent Genetics Inc (FLGT) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges ...May 4, 2024 | finance.yahoo.comQ1 2024 Fulgent Genetics Inc Earnings CallMay 3, 2024 | investorplace.comFLGT Stock Earnings: Fulgent Genetics Beats EPS, Misses Revenue for Q1 2024May 3, 2024 | msn.comOptions Volatility and Implied Earnings Moves Today, May 03, 2024May 3, 2024 | msn.comFulgent Genetics reports mixed Q1 results; reaffirms FY24 outlookMay 3, 2024 | finance.yahoo.comFulgent Genetics Inc (FLGT) Q1 2024 Earnings: Misses Analyst Forecasts with Wider LossesMay 3, 2024 | businesswire.comFulgent Reports First Quarter 2024 Financial ResultsMay 2, 2024 | markets.businessinsider.comFulgent Genetics is about to announce earnings — here's what Wall Street expectsSee More Headlines Receive FLGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/03/2024Today7/26/2024Next Earnings (Confirmed)8/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:FLGT CUSIPN/A CIK1674930 Webwww.fulgentgenetics.com Phone(626) 350-0537Fax626-454-1667Employees1,184Year Founded2011Price Target and Rating Average Stock Price Target$30.00 High Stock Price Target$35.00 Low Stock Price Target$25.00 Potential Upside/Downside+26.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($5.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-167,820,000.00 Net Margins-57.72% Pretax Margin-58.15% Return on Equity-2.92% Return on Assets-2.70% Debt Debt-to-Equity RatioN/A Current Ratio5.09 Quick Ratio5.09 Sales & Book Value Annual Sales$289.21 million Price / Sales2.45 Cash Flow$3.38 per share Price / Cash Flow7.01 Book Value$38.24 per share Price / Book0.62Miscellaneous Outstanding Shares29,920,000Free Float20,420,000Market Cap$707.91 million OptionableOptionable Beta1.37 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Ming Hsieh (Age 68)Chairman & CEO Comp: $2.31MMr. Jian Xie (Age 58)COO & President Comp: $868.74kMr. Paul Kim (Age 57)Chief Financial Officer Comp: $879.61kDr. Hanlin Gao D.A.B.M.G. (Age 57)FACMG, M.D., Ph.D., Chief Scientific Officer & Laboratory Director Comp: $720.7kMs. Natalie PrescottGeneral Counsel & Chief Privacy OfficerMs. Doreen NgVP of Operations & Compliance and GM of Houston OfficeMr. Jakub SramVice President of Business Development & SalesMs. Ellen TsuiVice President of Human ResourcesMr. Brandon PerthuisChief Commercial OfficerDr. Lawrence M. Weiss M.D. (Age 67)Chief Medical Officer More ExecutivesKey CompetitorsGenetronNASDAQ:GTHFortreaNASDAQ:FTRENational HealthCareNYSE:NHCTeladoc HealthNYSE:TDOCAdaptHealthNASDAQ:AHCOView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 55,020 shares on 7/26/2024Ownership: 0.672%TCW Group Inc.Bought 3,500 shares on 7/19/2024Ownership: 0.401%SG Americas Securities LLCBought 3,425 shares on 7/12/2024Ownership: 0.043%Comerica BankSold 1,324 shares on 5/17/2024Ownership: 0.029%Walleye Trading LLCBought 5,900 shares on 5/17/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions FLGT Stock Analysis - Frequently Asked Questions How have FLGT shares performed this year? Fulgent Genetics' stock was trading at $28.91 at the beginning of the year. Since then, FLGT shares have decreased by 18.2% and is now trading at $23.66. View the best growth stocks for 2024 here. How were Fulgent Genetics' earnings last quarter? Fulgent Genetics, Inc. (NASDAQ:FLGT) released its quarterly earnings data on Friday, May, 3rd. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.20. The firm earned $64.49 million during the quarter, compared to the consensus estimate of $65.74 million. Fulgent Genetics had a negative trailing twelve-month return on equity of 2.92% and a negative net margin of 57.72%. Does Fulgent Genetics have any subsidiaries? The following companies are subsidiaries of Fulgent Genetics: Inform Diagnostics, CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, and Fulgent Therapeutics LLC. When did Fulgent Genetics IPO? Fulgent Genetics (FLGT) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers. Who are Fulgent Genetics' major shareholders? Top institutional shareholders of Fulgent Genetics include Bank of New York Mellon Corp (0.67%), TCW Group Inc. (0.40%) and SG Americas Securities LLC (0.04%). Insiders that own company stock include Hanlin Gao, Jian Xie, Paul Kim and John C Bolger. View institutional ownership trends. How do I buy shares of Fulgent Genetics? Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Fulgent Genetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Block (SQ) and JD.com (JD). This page (NASDAQ:FLGT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulgent Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulgent Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
